1. Home
  2. SRDX vs DGICB Comparison

SRDX vs DGICB Comparison

Compare SRDX & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRDX
  • DGICB
  • Stock Information
  • Founded
  • SRDX 1979
  • DGICB 1986
  • Country
  • SRDX United States
  • DGICB United States
  • Employees
  • SRDX N/A
  • DGICB N/A
  • Industry
  • SRDX Medical/Dental Instruments
  • DGICB Property-Casualty Insurers
  • Sector
  • SRDX Health Care
  • DGICB Finance
  • Exchange
  • SRDX Nasdaq
  • DGICB Nasdaq
  • Market Cap
  • SRDX 562.6M
  • DGICB 504.0M
  • IPO Year
  • SRDX 1998
  • DGICB N/A
  • Fundamental
  • Price
  • SRDX $36.88
  • DGICB $14.88
  • Analyst Decision
  • SRDX Hold
  • DGICB
  • Analyst Count
  • SRDX 4
  • DGICB 0
  • Target Price
  • SRDX $43.00
  • DGICB N/A
  • AVG Volume (30 Days)
  • SRDX 276.5K
  • DGICB 783.0
  • Earning Date
  • SRDX 01-30-2025
  • DGICB 02-20-2025
  • Dividend Yield
  • SRDX N/A
  • DGICB 4.17%
  • EPS Growth
  • SRDX N/A
  • DGICB 148.60
  • EPS
  • SRDX N/A
  • DGICB 0.74
  • Revenue
  • SRDX $126,078,000.00
  • DGICB $979,119,004.00
  • Revenue This Year
  • SRDX $13.75
  • DGICB N/A
  • Revenue Next Year
  • SRDX $13.67
  • DGICB $5.78
  • P/E Ratio
  • SRDX N/A
  • DGICB $19.93
  • Revenue Growth
  • SRDX N/A
  • DGICB 7.44
  • 52 Week Low
  • SRDX $25.17
  • DGICB $10.75
  • 52 Week High
  • SRDX $42.44
  • DGICB $16.81
  • Technical
  • Relative Strength Index (RSI)
  • SRDX 34.51
  • DGICB 57.56
  • Support Level
  • SRDX $34.76
  • DGICB $13.90
  • Resistance Level
  • SRDX $37.08
  • DGICB $14.20
  • Average True Range (ATR)
  • SRDX 0.90
  • DGICB 0.30
  • MACD
  • SRDX -0.33
  • DGICB 0.00
  • Stochastic Oscillator
  • SRDX 38.90
  • DGICB 63.08

About SRDX Surmodics Inc.

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

About DGICB Donegal Group Inc. Class B

Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.

Share on Social Networks: